Loading stock…

Krystal Biotech, Inc. (KRYS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Krystal Biotech, Inc.

KRYSMarket cap $9.69BPrice $327.3

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops gene therapies delivered through a redosable herpes-simplex virus platform, treating rare genetic skin diseases at their root cause. Its first approved therapy, Vyjuvek, gives butterfly-skin patients something once unthinkable: real healing.

In Bastion Portfolios?

52W Return+72%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+29%9

Rev CAGR (3y)+30%10

Rev CAGR (5y)+31%10

Earnings Forecast

EPS Growth Y+1+170%10

EPS Growth Y+2+25%8

EPS Growth Y+3+54%9

Quality

Margins

EBIT Margin45%10

Net Income Margin55%10

Free Cash Flow Margin59%10

Debt

Net Debt/EBITDA-5.410

Efficiency

ROE20%8

ROA18%10

Earnings Stability66

GEAR+VERY STRONG96

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)332

P/E Ratio (Forward 3y)213

P/BV7.12

EV Multiples

EV/EBITDA Fwd351

EV/EBIT Fwd352

Yield

Free Cash Flow Yield2.7%4

Dividend Yieldna–

Momentum

Short term

1 month return-6%4

3 month return-12%3

YTD return+33%9

Mid term

Price vs 52wHigh86%7

1 year return+73%10

Long term

3 year return+179%9

5 year return+534%10

Risk Shield

Price Risk

Beta0.67

Volatility38%5

Free Cash Flow

Free Cash Flow Margin59%10

Free Cash Flow Yield2.7%4

Quality

ROCE16%8

Earnings Stability66

Net Debt/EBITDA-5.410

02Growth

Is it actually growing, and how fast?

KRYSKrystal Biotech

Revenue FY25$291M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+29%9

Revenue, next 3Y, CAGR+30%10

Revenue, next 5Y, CAGR+31%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+170%10

EPS growth, FY27E+25%8

EPS growth, FY28E+54%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue is set to grow 30%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 30%/yr from here.

The runway holds up: revenue is set to grow 31%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 54%/yr vs revenue 30%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG74 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-12%3

YTD return+33%9

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+73%10

3-year return+179%9

5-year return+534%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +179% over three years and +534% over five, ahead of 90% of the market.

It's up 73% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+33%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

The stock is underperforming over three months (-12%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Krystal Biotech, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

KRYSKrystal Biotech

Revenue FY25$291M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+29%9

Revenue, next 3Y, CAGR+30%10

Revenue, next 5Y, CAGR+31%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+170%10

EPS growth, FY27E+25%8

EPS growth, FY28E+54%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue is set to grow 30%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 30%/yr from here.

The runway holds up: revenue is set to grow 31%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 54%/yr vs revenue 30%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG74 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-12%3

YTD return+33%9

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+73%10

3-year return+179%9

5-year return+534%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +179% over three years and +534% over five, ahead of 90% of the market.

It's up 73% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+33%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

The stock is underperforming over three months (-12%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Krystal Biotech, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community